SciELO - Scientific Electronic Library Online

 
vol.8 número3Trastornos respiratorios del sueño en Insuficiencia Cardíaca con fracción de eyección reducida.COVID-19 y Enfermedades Autoinmunes Sistémicas ¿cuál es la relación y sus consecuencias? índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Links relacionados

Compartir


Revista Uruguaya de Medicina Interna

versión On-line ISSN 2393-6797

Resumen

CAMEJO, Natalia et al. Clinical-pathological characteristics and evolution of breast cancer in patients assisted in the Mastology Unit of the Hospital de Clínicas. Rev. Urug. Med. Int. [online]. 2023, vol.8, n.3, pp.16-25.  Epub 01-Dic-2023. ISSN 2393-6797.  https://doi.org/10.26445/08.03.2.

Introduction:

In Uruguay, breast cancer (BC) ranks first in incidence and mortality from cancer in women. It is a multifactorial disease that is related to genetic inheritance, estrogenic hormonal history, lifestyle, environmental and cultural factors.

Objectives:

to investigate the clinicopathological characteristics of patients with BC diagnosed at the Hospital de Clínicas and to evaluate the overall overall survival (SVG) and according to the biological subtype.

Metodology:

data related to the clinicopathological characteristics and the evolution of patients treated for BC in the period between January 1, 2011 and December 31, 2020 assisted in the Mastology Unit of the Hospital de Clínicas were collected. Overall survival (SVG) was calculated for all patients, globally, and according to biological subtype.

Results:

390 patients were included. The clinicopathological characteristics were: ductal carcinoma: 83%, stage: in situ (1.8%), I (27.7%), II (29.7%), III (23.6%), IV (12.6%). Regarding the biological profile: 235 tumors (60.3%) were HR+ HER 2−, 88 tumors (22.6%) were HER2 +, while another 41 tumors (10.5%) were classified as triple negative (TN). The SVG for all the patients had a median of 92 months. SVG rates at 2 and 5 years were 92% and 64% for luminals; in TN the 24-month survival rate was 69%, being 53.3% at 5 years and in HER2 + 76.6% and 67.3% respectively.

Conclusions:

Most of the tumors were diagnosed in early stages, these data being consistent with those reported in studies carried out at the national level. The frequency of ER/RP+ tumors was somewhat lower than that reported in previous studies (70%) at the national level, while that of HER 2 + TN tumors was similar to that reported in European, North American and Latin American studies where the prevalence found is 20%

Palabras clave : Neoplasms of the breast; Clinicopathological features; Survived.

        · resumen en Español | Portugués     · texto en Español     · Español ( pdf )